Eg ibuprofen - medication for fever and pain 150 ml strawberry

Product Description

Antipyretic drug for children

Indications

Symptomatic treatment of fever and mild to moderate pain.

Composition

Active ingredients

Ibuprofen

Excipients

100mg/5ml sugar-free strawberry-flavored oral suspension: citric acid monohydrate, sodium citrate, acesulfame potassium, xanthan gum, sodium benzoate, strawberry flavoring, maltitol syrup, glycerin, purified water.

Directions for use and Dosage

The daily dose is structured according to the weight and age of the patient.
Undesirable effects can be minimized by using the lowest effective dose for the longest duration of treatment. short as necessary to control symptoms.
In children aged between 3 and 6 months, limit administration to those weighing more than 5.6 kg.

Oral administration to infants and children aged between 3 months and 12 years should be done using the dosing syringe supplied with the product.
The graduated scale on the body of the syringe clearly shows the notches for the different dosages; in particular, the 2.5 ml mark corresponding to 50 mg of ibuprofen and the 5 ml mark corresponding to 100 mg of ibuprofen.
The daily dose of 20-30 mg/kg of body weight, divided 3 times a day at intervals of 6-8 hours, can be be administered according to the following schedule.

Weight 5.6 - 7 kg (3 - 6 months): 2.5.
Weight 7 - 10 kg (6 - 12 months): 2.5 ml.
Weight 10 - 15 kg (1 - 3 years): 5 ml.
Weight 15 - 20 kg (4 - 6 years): 7.5 ml (5 ml + 2.5 ml).
Weight 20 - 28 kg (7 - 9 years): 10 ml.
Weight 28 - 43 kg (10 - 12 years): 15 ml.

The maximum number of administrations is 3 in 24 hours.
In case of post-vaccination fever, refer to the dosage indicated above, administering a single dose followed, if necessary, by another dose after 6 hours. Do not administer more than two doses in 24 hours.
The product is intended for short-term treatments.

If the use of the medicine is necessary for more than 3 days in infants and children over 6 months of age and in adolescents, or in case of worsening of symptoms, a doctor must be consulted.
In infants between 3 and 5 months of age, a doctor must be consulted if the symptoms persist for a period of more than 24 hours or in case of worsening of symptoms.
Instructions for using the dosing syringe: unscrew the cap by pushing it downwards and turning it to the left; insert the tip of the syringe fully into the hole in the undercap; shake well; Turn the bottle upside down, then, holding the syringe firmly, gently pull the plunger downwards, allowing the suspension to flow into the syringe up to the mark corresponding to the desired dose; return the bottle to the upright position and remove the syringe by gently rotating it; insert the tip of the syringe into the child's mouth and apply gentle pressure to the plunger to allow the suspension to flow.
After use, screw the cap on the bottle and wash the syringe with warm water.
Leave it to dry, keeping it out of the reach and sight of children.

Pregnancy and breastfeeding

It is unlikely that subjects under 12 years of age will become pregnant or breastfeed.
However, in such circumstances the following considerations should be taken into account.
Inhibition of prostaglandin synthesis may cause serious side effects. negatively affect pregnancy and/or embryo/fetal development.
Results of epidemiological studies suggest an increased risk of miscarriage and cardiac malformation and gastroschisis after use of a prostaglandin synthesis inhibitor in early pregnancy.
The risk is believed to increase with dose and duration of therapy.
In animals, administration of prostaglandin synthesis inhibitors has been shown to result in increased pre- and post-implantation loss and embryo-fetal mortality.
Furthermore, an increased incidence of various malformations, including cardiovascular, has been reported in animals administered prostaglandin synthesis inhibitors during the organogenetic period.
During the third trimester of pregnancy, all prostaglandin synthesis inhibitors may expose the fetus to: cardiopulmonary toxicity (with premature closure of the ductus arteriosus and pulmonary hypertension); renal dysfunction which may progress to renal failure with oligo-hydroamniosis; the mother and the newborn, at the end of pregnancy, to: possible prolongation of bleeding time, an antiplatelet effect which may occur even at very low doses; inhibition of uterine contractions resulting in delayed or prolonged labor.

Format

150 ml